SLC5A2 and chronic kidney disease: A meta-analysis of 10 RCTs involving approximately 17,000 patients revealed that the addition of SGLT2 inhibitors to RAS blockers significantly reduced cardiovascular death, end-stage renal disease progression, and albuminuria compared to RAS blockers alone [176].